Medical oncologist David Hyman leads the Early Drug Development Service.
Nearly every treatment that is available to patients today has come about because of a clinical trial. At MSK, we strive to lead the way in every stage of the research process.
The Early Drug Development Service (EDD) represents MSK’s commitment to provide access to exciting new therapies for our adult and pediatric patients from the very earliest stages when they first enter the clinic.
In our Service, our doctors and scientists work together to expand our drug development initiatives and our patients benefit from close communication with their healthcare team.
The EDD supports the Department of Medicine, the Human Oncology & Pathogenesis Program, and the Sloan Kettering Institute, and works closely with the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Precision Pathology Biobanking Center, Functional Genomics Initiative, the Center for Epigenetics Research, and the Brain Tumor Center, among others.
David Hyman
Chief, Early Drug Development Service
Wassim Abida
Alexander Drilon
Research Director, Early Drug Development
Mrinal M. Gounder
James J. Harding
Regional Director, Early Drug Development
Gopa Iyer
Komal Jhaveri
Bob T. Li
Physician Ambassador to China and Asia-Pacific, Bobst International Center
Alison Schram
Contact Us
David Hyman
Chief, Early Drug Development Service
hymand@mskcc.org
